ArticleThe Journal of pediatrics2010
Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids.
Article in The Journal of pediatrics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 29 citations in OpenAlex.
- Review
- Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.Rheumatic diseases clinics of North America · 2021Review
- Favorable outcomes with reduced steroid use in juvenile dermatomyositis.Pediatric rheumatology online journal · 2021Article
- Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.Current rheumatology reports · 2021Review
- Treatment of Calcinosis in Juvenile Dermatomyositis.Current rheumatology reports · 2021Review
- Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.Pediatric rheumatology online journal · 2018Article
- Treatment of Juvenile Dermatomyositis: An Update.Paediatric drugs · 2017Review
- Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis.Clinical rheumatology · 2014Article
- Novel approaches in the treatment of myositis and myopathies.Therapeutic advances in musculoskeletal disease · 2012Article
- Autoimmune neuromuscular disorders in childhood.Current treatment options in neurology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo describe the course of patients with juvenile dermatomyositis (JDM) treated effectively without systemic corticosteroids. STUDY
designA retrospective study of 38 patients with JDM treated at a tertiary care children's hospital identified 8 patients who had never received corticosteroids. Disease presentation and course, pharmacologic, and ancillary treatments were recorded.
resultsPatients in the no corticosteroid group were followed for a median of 2.8 years (range, 2.1 to 9.5 years). Treatment was primarily with intravenous immunoglobulin (IVIG) (75%) and methotrexate (50%), with favorable response in all. No serious treatment complications were observed; headaches were reported by 3 patients receiving IVIG. Two patients had a myositis flare after discontinuing all medications for more than 1 year; complete resolution of symptoms was observed after either 1 or 2 further doses of IVIG. Two patients had calcinosis (at 1 and 9 years of disease); however, no patient had joint contractures, muscle atrophy, lipodystrophy, or functional limitations.
conclusionsSystemic corticosteroids can be avoided in a select group of patients with JDM. Alternative agents such as methotrexate and IVIG may be prescribed to effectively treat JDM and prevent complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.